Ipsen advances liver disease treatment

Beyond Biotech - the podcast from Labiotech

Το περιεχόμενο παρέχεται από το Labiotech. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Labiotech ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

1y ago 21:47

MP3•Αρχική οθόνη επεισοδίου

Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen.

On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.

00:56-00:49: Background information
01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease?
03:21-03:50: How rare is PBC?
03:50-04:45: How easy is PBC diagnosis?
04:45-05:45: What are the current treatments for the condition?
05:45-07:22: What are the challenges to innovation?
07:22-08:27: What is elafibranor?
08:27-08:37: How is it administered?
08:37-09:18: Is elafibranor taken for life?
09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting?
11:08-13:09: What was the reaction at the meeting?
13:09-13:55: A patient-centric approach
13:55-14:44: Is a cure for PBC a possibility?
14:44-17:20: How important are acquisitions to Ipsen’s pipeline?
17:20-18:33: Working on multiple diseases
18:33-19:58: How much impact can you have on liver diseases?
19:58-21:04: What are the next steps for elafibranor?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Κεφάλαια

1. Ipsen advances liver disease treatment (00:00:00)

2. Background information (00:00:56)

3. What are primary biliary cholerangitis (PBC) and cholestatic liver disease? (00:01:44)

4. How rare is PBC? (00:03:21)

5. How easy is PBC diagnosis? (00:03:50)

6. What are the current treatments for the condition? (00:04:45)

7. What are the challenges to innovation? (00:05:45)

8. What is elafibranor?  (00:07:22)

9. Is elafibranor taken for life?  (00:08:27)

10. How is elafibranor administered?  (00:08:27)

11. What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting? (00:09:18)

12. What was the reaction at the meeting?  (00:11:08)

13. A patient-centric approach  (00:13:09)

14. Is a cure for PBC a possibility?  (00:13:55)

15. How important are acquisitions to Ipsen’s pipeline?  (00:14:44)

16. Working on multiple diseases  (00:17:20)

17. How much impact can you have on liver diseases?  (00:18:33)

18. What are the next steps for elafibranor?  (00:19:58)

136 επεισόδια

#News #Tech News #Labiotech